{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:06:28Z","timestamp":1791983188721,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clbc.2025.03.018","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:48:36Z","timestamp":1743778116000},"page":"493-507.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early Breast Cancer Treatment and Cardiac Events: A Systematic Review"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-4695","authenticated-orcid":false,"given":"Nicolas","family":"Meillan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gueiderikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assia","family":"Lamrani-Ghaouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"De Vathaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigue Setcheou","family":"Allodji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clbc.2025.03.018_bib0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2025.03.018_bib0002","series-title":"AJCC Cancer Staging Manual [Internet]","author":"Amin","year":"2018"},{"key":"10.1016\/j.clbc.2025.03.018_bib0003","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"9","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"9935","key":"10.1016\/j.clbc.2025.03.018_bib0004","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","year":"2014","journal-title":"The Lancet."},{"issue":"9804","key":"10.1016\/j.clbc.2025.03.018_bib0005","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials","volume":"378","year":"2011","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.clbc.2025.03.018_bib0006","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.clbc.2025.03.018_bib0007","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol."},{"issue":"5","key":"10.1016\/j.clbc.2025.03.018_bib0008","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2021.0023","article-title":"NCCN Guidelines\u00ae insights: breast cancer, Version 4.2021: featured updates to the NCCN Guidelines","volume":"19","author":"Gradishar","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"issue":"41","key":"10.1016\/j.clbc.2025.03.018_bib0009","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J."},{"key":"10.1016\/j.clbc.2025.03.018_bib0010","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"25","key":"10.1016\/j.clbc.2025.03.018_bib0011","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.clbc.2025.03.018_bib0012","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jamaoncol.2016.6120","article-title":"Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial","volume":"3","author":"Joensuu","year":"2017","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.clbc.2025.03.018_bib0013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0014","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.clbc.2025.03.018_bib0015","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol."},{"issue":"9917","key":"10.1016\/j.clbc.2025.03.018_bib0016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(13)61950-9","article-title":"Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-a randomised trial","volume":"383","author":"Vaidya","year":"2014","journal-title":"The Lancet."},{"issue":"10099","key":"10.1016\/j.clbc.2025.03.018_bib0017","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"390","author":"Coles","year":"2017","journal-title":"The Lancet."},{"issue":"5","key":"10.1016\/j.clbc.2025.03.018_bib0018","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijrobp.2013.03.021","article-title":"Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy","volume":"86","author":"Hennequin","year":"2013","journal-title":"Int J Radiat Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0019","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"8","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","article-title":"Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jacc.2010.08.638","article-title":"Long-term cardiovascular mortality after radiotherapy for breast cancer","volume":"57","author":"Bouillon","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.clbc.2025.03.018_bib0022","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/dji067","article-title":"Risk of cardiac death after adjuvant radiotherapy for breast cancer","volume":"97","author":"Giordano","year":"2005","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"9188","key":"10.1016\/j.clbc.2025.03.018_bib0023","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(99)02245-X","article-title":"Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials","volume":"354","author":"H\u00f8jris","year":"1999","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0024","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0360-3016(98)00412-X","article-title":"Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada","volume":"43","author":"Paszat","year":"1999","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00062-0","article-title":"Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer","volume":"48","author":"Gyenes","year":"1998","journal-title":"Radiother Oncol."},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0026","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0360-3016(03)00594-7","article-title":"Cardiovascular death and second non\u2013breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy","volume":"57","author":"Woodward","year":"2003","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijrobp.2007.03.033","article-title":"Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer","volume":"69","author":"Marhin","year":"2007","journal-title":"Int J Radiat Oncol."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0028","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijrobp.2020.04.003","article-title":"No increased cardiac mortality or morbidity of radiation therapy in breast cancer patients after breast-conserving surgery: 20-year follow-up of the randomized SweBCGRT trial","volume":"107","author":"Killander","year":"2020","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0029","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0360-3016(97)00765-7","article-title":"Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation","volume":"40","author":"Rutqvist","year":"1998","journal-title":"Int J Radiat Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.breast.2017.12.006","article-title":"Associations between adjuvant radiotherapy and different causes of death in a German breast cancer cohort","volume":"38","author":"Obi","year":"2018","journal-title":"The Breast."},{"issue":"8","key":"10.1016\/j.clbc.2025.03.018_bib0031","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2407-7-9","article-title":"Increased Cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study","volume":"7","author":"Roychoudhuri","year":"2007","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10549-021-06412-3","article-title":"Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)","volume":"191","author":"Merzenich","year":"2022","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.clbc.2025.03.018_bib0034","volume":"11","author":"Lim","year":"2021"},{"issue":"6688","key":"10.1016\/j.clbc.2025.03.018_bib0035","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/bmj.298.6688.1611","article-title":"Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer","volume":"298","author":"Haybittle","year":"1989","journal-title":"Br Med J."},{"key":"10.1016\/j.clbc.2025.03.018_bib0036","first-page":"1342","volume":"3","author":"Onwudiwe","year":"2014"},{"key":"10.1016\/j.clbc.2025.03.018_bib0037","first-page":"249","volume":"166","author":"Chang","year":"2017"},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0038","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-016-4045-z","article-title":"Trends in cardiac mortality in women with ductal carcinoma in situ","volume":"161","author":"Haque","year":"2017","journal-title":"Breast Cancer Res Treat."},{"issue":"25","key":"10.1016\/j.clbc.2025.03.018_bib0039","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.1037","article-title":"Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment","volume":"24","author":"Harris","year":"2006","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.clbc.2025.03.018_bib0040","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.radonc.2012.10.016","article-title":"Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients","volume":"106","author":"Nissen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clbc.2025.03.018_bib0042","first-page":"474","volume":"27","author":"Bourgier","year":"2016"},{"key":"10.1016\/j.clbc.2025.03.018_bib0043","first-page":"366","volume":"22","author":"Boekel","year":"2020"},{"issue":"3","key":"10.1016\/j.clbc.2025.03.018_bib0044","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijrobp.2018.10.025","article-title":"Radiation dose-response for risk of myocardial infarction in breast cancer survivors","volume":"103","author":"Jacobse","year":"2019","journal-title":"Int J Radiat Oncol. mars"},{"key":"10.1016\/j.clbc.2025.03.018_bib0045","first-page":"595","volume":"163","author":"Wollschlager","year":"2017"},{"key":"10.1016\/j.clbc.2025.03.018_bib0046","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.radonc.2020.08.007","article-title":"Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977\u20132005","volume":"152","author":"Laugaard Lorenzen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clbc.2025.03.018_bib0047","unstructured":"Elsevier Enhanced Reader. Hypofractionated Breast Radiotherapy for 1 Week versus 3 Weeks (FAST-Forward): 5-Year Efficacy And Late Normal Tissue Effects Results From a Multicentre, Non-Inferiority, Randomised, Phase 3 Trial, Elsevier Enhanced Reader. Disponible sur: https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S0140673620309326?token=B560CF958597F72847079E9A614D44CCD4D650C619565168B1688B12C6AC9CE78B4EC87843AD5EE7A7CD4488311E7BEE&originRegion=eu-west-1&originCreation=20220225212152. Accessed December 31, 2024."},{"issue":"10350","key":"10.1016\/j.clbc.2025.03.018_bib0048","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3\u201307\/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study","volume":"400","author":"Chua","year":"2022","journal-title":"The Lancet."},{"issue":"13","key":"10.1016\/j.clbc.2025.03.018_bib0049","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(13)70497-2","article-title":"Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial","volume":"14","author":"Veronesi","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejca.2014.12.013","article-title":"Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial","volume":"51","author":"Livi","year":"2015","journal-title":"Eur J Cancer."},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0051","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1470-2045(17)30011-6","volume":"18","author":"Polg\u00e1r","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0052","first-page":"317","volume":"373","author":"Poortmans","year":"2015"},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0053","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1415340","article-title":"Regional nodal irradiation in early-stage breast cancer","volume":"373","author":"Whelan","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0054","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2015.63.6456","article-title":"DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer","volume":"34","author":"Thorsen","year":"2016","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.clbc.2025.03.018_bib0055","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/ijc.32908","article-title":"Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries","volume":"147","author":"Henson","year":"2020","journal-title":"Int J Cancer."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0056","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2015.12.018","article-title":"Modern radiation therapy and cardiac outcomes in breast cancer","volume":"94","author":"Boero","year":"2016","journal-title":"Int J Radiat Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0057","first-page":"98","volume":"55","author":"Tan","year":"2016"},{"key":"10.1016\/j.clbc.2025.03.018_bib0058","first-page":"6084","volume":"7","author":"Kim","year":"2018"},{"issue":"9814","key":"10.1016\/j.clbc.2025.03.018_bib0059","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials","volume":"379","year":"2012","journal-title":"The Lancet."},{"issue":"22","key":"10.1016\/j.clbc.2025.03.018_bib0060","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0061","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2020.02.010","article-title":"Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity","volume":"20","author":"Sherry","year":"2020","journal-title":"Clin Breast Cancer."},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0062","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2011.35.4639","article-title":"Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial","volume":"30","author":"Joensuu","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0063","first-page":"709","article-title":"Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study","volume":"18","author":"Bliss","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0064","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2007.11.6798","article-title":"Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen","volume":"26","author":"Goss","year":"2008","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0065","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0066","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.clbc.2025.03.018_bib0067","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0068","first-page":"1273","volume":"365","author":"Slamon","year":"2011"},{"key":"10.1016\/j.clbc.2025.03.018_bib0069","first-page":"741","volume":"14","author":"Pivot","year":"2013"},{"issue":"10","key":"10.1016\/j.clbc.2025.03.018_bib0070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2\u2013positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0071","first-page":"2328","volume":"29","author":"Conte","year":"2018"},{"key":"10.1016\/j.clbc.2025.03.018_bib0072","first-page":"1195","volume":"389","author":"Cameron","year":"2017"},{"key":"10.1016\/j.clbc.2025.03.018_bib0073","first-page":"2599","volume":"393","author":"Earl","year":"2019"},{"issue":"7","key":"10.1016\/j.clbc.2025.03.018_bib0074","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer."},{"issue":"4","key":"10.1016\/j.clbc.2025.03.018_bib0076","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4048\/jbc.2020.23.e45","article-title":"Updated Bayesian network meta-analysis of adjuvant targeted treatment regimens for early human epidermal growth factor receptor-2 positive breast cancer","volume":"23","author":"Li","year":"2020","journal-title":"J Breast Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0077","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0078","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.clbc.2025.03.018_bib0079","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.clbc.2025.03.018_bib0080","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med."},{"issue":"10257","key":"10.1016\/j.clbc.2025.03.018_bib0081","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.clbc.2025.03.018_bib0082","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0083","volume":"8","author":"Chowdhary","year":"2019"},{"issue":"11","key":"10.1016\/j.clbc.2025.03.018_bib0084","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/14740338.2022.2151584","article-title":"Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects","volume":"21","author":"Di Nardo","year":"2022","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"10.1016\/j.clbc.2025.03.018_bib0085","first-page":"8","article-title":"Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study","volume":"33","author":"Kuroda","year":"2025","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2025.03.018_bib0086","article-title":"Cardiovascular health considerations for primary care physicians treating breast cancer survivors","author":"Kidane","year":"2024","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.clbc.2025.03.018_bib0087","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2147\/OTT.S65653","article-title":"Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?","author":"Aprile","year":"2014","journal-title":"OncoTargets Ther."},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0088","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.clbc.2025.03.018_bib0089","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc."},{"issue":"3","key":"10.1016\/j.clbc.2025.03.018_bib0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.radonc.2017.01.008","article-title":"A cardiac contouring atlas for radiotherapy","volume":"122","author":"Duane","year":"2017","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0091","first-page":"106","volume":"157","author":"Milo","year":"2021"},{"key":"10.1016\/j.clbc.2025.03.018_bib0092","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.71562","article-title":"Risk of heart disease following treatment for breast cancer \u2013 results from a population-based cohort study","volume":"11","author":"Yang","year":"2022","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.clbc.2025.03.018_bib0093","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.radonc.2007.01.004","article-title":"A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer","volume":"82","author":"Paszat","year":"2007","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.clbc.2025.03.018_bib0094","first-page":"567","volume":"67","author":"Leung","year":"2016"},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-015-3481-5","article-title":"A higher incidence rate of acute coronary syndrome following radiation therapy in patients with breast cancer and a history of coronary artery diseases","volume":"152","author":"Lee","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.03.018_bib0096","first-page":"629","volume":"195","author":"Lee","year":"2019"},{"key":"10.1016\/j.clbc.2025.03.018_bib0097","first-page":"48","volume":"43","author":"Chang","year":"2019"},{"key":"10.1016\/j.clbc.2025.03.018_bib0098","first-page":"1061","volume":"94","author":"Boekel","year":"2016"},{"issue":"2","key":"10.1016\/j.clbc.2025.03.018_bib0099","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/jcrt.jcrt_1212_21","article-title":"Target volume coverage in clinically designed radiotherapy plan of post-mastectomy adjuvant radiotherapy of breast cancer patients in comparison with radiation therapy oncology group-based contoured plan: A dosimetric study","volume":"19","author":"Azam","year":"2023","journal-title":"J Cancer Res Ther [Internet]"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:16:34Z","timestamp":1752765394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1526820925000850"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.03.018","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Breast Cancer Treatment and Cardiac Events: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}